Spinal muscular atrophy is a condition that is being worked on in order to find an effective treatment pathway. In December 2016, the first results of a study of a treatment for this condition using nusinersen were published. The drug showed great efficacy - significant improvements were observed not only in relation to the tests conducted on animals, but also in relation to studies on a group of children with a very poor prognosis. The treatment effects were so positive that the drug was approved for the treatment of spinal muscular atrophy by the US Food and Drug Administration.